Clinical Trials
15
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
An Observational Study of Patients With Autoimmune Disease
- Conditions
- Autoimmune Diseases
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Target Recruit Count
- 500000
- Registration Number
- NCT05842824
An Observational Study of Patients With Metabolic Syndrome and Related Conditions
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Target Recruit Count
- 2000000
- Registration Number
- NCT05842811
An Observational Study of Patients Living With Chronic Neurological Diseases
- Conditions
- Neurological Diseases or ConditionsDementia of Alzheimer TypeAlzheimer DiseaseMild Cognitive ImpairmentMultiple SclerosisParkinson Disease
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Target Recruit Count
- 1500000
- Registration Number
- NCT05796037
An Observational Study of Patients With Chronic Kidney Disease
- Conditions
- Kidney Disease, ChronicEnd Stage Kidney Disease
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Target Recruit Count
- 500000
- Registration Number
- NCT05774392
An Observational Study of Patients with Chronic Gastrointestinal Disease
- Conditions
- Gastrointestinal Diseases
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Target PharmaSolutions, Inc.
- Target Recruit Count
- 500000
- Registration Number
- NCT05774080
- Locations
- 🇺🇸
Atrium Health/Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
- Prev
- 1
- 2
- 3
- Next
News
Type 2 Diabetes Significantly Increases Risk of MASH Progression to Cirrhosis, New Target RWE Study Reveals
New research from Target RWE presented at EASL 2025 demonstrates that individuals with Type 2 diabetes have significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group.
Target RWE Showcases Groundbreaking Liver Disease Research at EASL Congress 2025
• Target RWE presented significant findings on MASH and HCC at EASL Congress 2025, revealing that Type 2 diabetes substantially increases the risk of progression to MASH-related cirrhosis. • The company's Chief Medical Officer participated in the PBC Consensus Conference, focusing on developing surrogate endpoints and integrating real-world evidence into clinical trials for Primary Biliary Cholangitis. • With over 600,000 patients enrolled in its TARGET-Liver Disease observational study, Target RWE continues to advance understanding of chronic liver diseases through its partnership with the American Association for the Study of Liver Diseases.